Acetylcholinesterase (AChE) plays an important role in the pathogenesis of
neurodegenerative diseases by influencing the inflammatory response, apoptosis, oxidative …

The word dementia describes a class of heterogeneous diseases which etiopathogenetic
mechanisms are not well understood. There are different types of dementia, among which …

Background: Alzheimer's disease (AD) and other forms of dementia are among the most
common causes of disability in the elderly. Dementia is often accompanied by depression …

The development of depressive disorders had long been attributed to monoamine
variations, and pharmacological treatment strategies likewise focused on methods of …

Background The treatment of depression in old age is complicated by frequent co-morbidity
with cognitive impairment. Anti-dementia drugs have some efficacy to improve cognitive …

Introduction: Pharmacotherapy for the treatment of depressive disorders in Alzheimer's
Disease (AD) represents a clinical challenge. pharmacological options are often attempted …

Finding new antidepressant agents is of high clinical priority given that many cases of major
depressive disorder (MDD) do not respond to conventional monoaminergic antidepressants …

Introduction Improvement of cognitive function may be desirable for healthy individuals and
clinically beneficial for those with cognitive impairment such as from Alzheimer's disease …

Objectives To investigate whether acetylcholinesterase inhibitor (AChEI) use prevents or
delays subsequent initiation of psychotropic medications in people with Alzheimer's disease …

Rivastigmine is a non-competitive inhibitor of both acetylcholinesterase (AChE) and
butylcholinesterase (BuChE) used to treat mild to moderate dementia in Alzheimer's disease …